Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.
about
Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trialsBendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data.Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion.Spotlight on lenalidomide in relapsed or refractory multiple myeloma.Thalidomide: an old drug with new action.Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma.Pomalidomide: first global approval.Pomalidomide: a review of its use in patients with recurrent multiple myeloma.Therapy-related peripheral neuropathy in multiple myeloma patients.Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.Lenalidomide: a review of its continuous use in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation.Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells.A population-based analysis of the effect of autologous hematopoietic cell transplant in the treatment of multiple myeloma.Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales.Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma
P2860
Q21133524-0F03C2F8-A674-46F0-9E8C-BB943CCA4865Q30828090-F9421885-953A-4C1A-BBD2-EC4B59B28422Q33408873-35393DE6-01E1-445B-B57B-535AD42E4984Q34028642-B93A5F6F-B0DC-4E8E-836A-D793EDC940A9Q37974744-A4C98C81-114B-479A-818C-01B8F5892114Q38040846-AE2C3521-576F-4823-A81C-FDEF6491D88AQ38097747-080BF750-821A-4488-94AB-C9E27BE8383DQ38192969-63B609D4-F337-45F5-BB32-147F3C687E9FQ38268525-BB8FED04-2DD4-47D1-B579-E0D2739D2F96Q38413040-9281CADA-8F80-4299-B7B1-5866529C4A76Q38450335-549B4B0C-2BEE-4498-8694-4A8F92F458FFQ38632778-FE80CBDA-31C9-4063-886C-7F09E22AAC42Q39168624-1C13498D-D9BE-4CC3-9820-5FD92FED1339Q44282317-0181E513-9A64-408A-BE19-9AF31D2FC02DQ47786014-815A137D-AD08-4F12-9085-17583C664208Q55058300-D4916647-CA18-4ECC-974D-3E98B105970CQ57904195-75360627-8F9C-4565-B8FC-4A966EE36256
P2860
Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Lenalidomide: a review of its ...... r refractory multiple myeloma.
@en
Lenalidomide: a review of its ...... r refractory multiple myeloma.
@nl
type
label
Lenalidomide: a review of its ...... r refractory multiple myeloma.
@en
Lenalidomide: a review of its ...... r refractory multiple myeloma.
@nl
altLabel
Lenalidomide
@en
prefLabel
Lenalidomide: a review of its ...... r refractory multiple myeloma.
@en
Lenalidomide: a review of its ...... r refractory multiple myeloma.
@nl
P2860
P1433
P1476
Lenalidomide: a review of its ...... r refractory multiple myeloma.
@en
P2860
P304
P356
10.2165/11206420-000000000-00000
P577
2011-03-01T00:00:00Z